Treatment with antiangiogenic drugs in multiple lines in patients with metastatic colorectal cancer: meta-analysis of randomized trials

Background. In metastatic colorectal cancer (mCRC), continuing antiangiogenic drugs beyond progression might provide clinical benefit. We synthesized the available evidence in a meta-analysis. Patients and Methods. We conducted a meta-analysis of studies investigating the use of antiangiogenic drugs...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hofheinz, Ralf-Dieter (VerfasserIn) , Ronellenfitsch, Ulrich (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2016
In: Gastroenterology research and practice

ISSN:1687-630X
DOI:undefined
Online-Zugang:Verlag, Volltext: http://dx.doi.org/undefined
Verlag, Volltext: https://www.hindawi.com/journals/grp/2016/9189483/
Volltext
Verfasserangaben:R.-D. Hofheinz, U. Ronellenfitsch, S. Kubicka, A. Falcone, I. Burkholder, and U.T. Hacker

MARC

LEADER 00000caa a2200000 c 4500
001 1587334917
003 DE-627
005 20230427034231.0
007 cr uuu---uuuuu
008 190206s2016 xx |||||o 00| ||eng c
035 |a (DE-627)1587334917 
035 |a (DE-576)517334917 
035 |a (DE-599)BSZ517334917 
035 |a (OCoLC)1341036923 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Hofheinz, Ralf-Dieter  |d 1969-  |e VerfasserIn  |0 (DE-588)121917517  |0 (DE-627)08161876X  |0 (DE-576)292991568  |4 aut 
245 1 0 |a Treatment with antiangiogenic drugs in multiple lines in patients with metastatic colorectal cancer  |b meta-analysis of randomized trials  |c R.-D. Hofheinz, U. Ronellenfitsch, S. Kubicka, A. Falcone, I. Burkholder, and U.T. Hacker 
264 1 |c 2016 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 06.02.2019 
520 |a Background. In metastatic colorectal cancer (mCRC), continuing antiangiogenic drugs beyond progression might provide clinical benefit. We synthesized the available evidence in a meta-analysis. Patients and Methods. We conducted a meta-analysis of studies investigating the use of antiangiogenic drugs beyond progression. Eligible studies were randomized phase II/III trials. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints were the impact of continuing antiangiogenic drugs (i) in subgroups, (ii) in different types of compounds targeting the VEGF-axis (monoclonal antibodies versus tyrosine kinase inhibitors), and (iii) on remission rates and prevention of progression. Results. Eight studies (3,668 patients) were included. Continuing antiangiogenic treatment beyond progression significantly improved PFS (HR 0.64; 95%-CI, 0.55-0.75) and OS (HR 0.83; 95%-CI, 0.76-0.89). PFS was significantly improved in all subgroups with comparable HR. OS was improved in all subgroups stratified by age, gender, and ECOG status. The rate of patients achieving at least stable disease was improved with an OR of 2.25 (95%-CI, 1.41-3.58). Conclusions. This analysis shows a significant PFS and OS benefit as well as a benefit regarding disease stabilization when using antiangiogenic drugs beyond progression in mCRC. Future studies should focus on the optimal sequence of administering antiangiogenic drugs. 
700 1 |a Ronellenfitsch, Ulrich  |d 1977-  |e VerfasserIn  |0 (DE-588)13178322X  |0 (DE-627)513952179  |0 (DE-576)29874144X  |4 aut 
773 0 8 |i Enthalten in  |t Gastroenterology research and practice  |d [Hoboken, NJ : Wiley], 2008  |g (2016) Artikel-Nummer 9189483, 9 Seiten  |h Online-Ressource  |w (DE-627)571608647  |w (DE-600)2435460-0  |w (DE-576)283869534  |x 1687-630X  |7 nnas  |a Treatment with antiangiogenic drugs in multiple lines in patients with metastatic colorectal cancer meta-analysis of randomized trials 
773 1 8 |g year:2016  |g extent:9  |a Treatment with antiangiogenic drugs in multiple lines in patients with metastatic colorectal cancer meta-analysis of randomized trials 
856 4 0 |u http://dx.doi.org/undefined  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://www.hindawi.com/journals/grp/2016/9189483/  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20190206 
993 |a Article 
994 |a 2016 
998 |g 13178322X  |a Ronellenfitsch, Ulrich  |m 13178322X:Ronellenfitsch, Ulrich  |d 60000  |d 61800  |e 60000PR13178322X  |e 61800PR13178322X  |k 0/60000/  |k 1/60000/61800/  |p 2 
998 |g 121917517  |a Hofheinz, Ralf-Dieter  |m 121917517:Hofheinz, Ralf-Dieter  |d 60000  |d 65500  |e 60000PH121917517  |e 65500PH121917517  |k 0/60000/  |k 1/60000/65500/  |p 1  |x j 
999 |a KXP-PPN1587334917  |e 3055142616 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"pubHistory":["1.2008 -"],"language":["eng"],"part":{"year":"2016","text":"(2016) Artikel-Nummer 9189483, 9 Seiten","extent":"9"},"title":[{"title":"Gastroenterology research and practice","title_sort":"Gastroenterology research and practice"}],"note":["Gesehen am 27.07.2021"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["571608647"],"zdb":["2435460-0"],"issn":["1687-630X"],"doi":["10.1155/GRP"]},"disp":"Treatment with antiangiogenic drugs in multiple lines in patients with metastatic colorectal cancer meta-analysis of randomized trialsGastroenterology research and practice","origin":[{"publisherPlace":"[Hoboken, NJ ; New York, NY","publisher":"Wiley] ; Hindawi","dateIssuedDisp":"2024-","dateIssuedKey":"2024"}],"recId":"571608647","type":{"bibl":"periodical","media":"Online-Ressource"}}],"note":["Gesehen am 06.02.2019"],"id":{"eki":["1587334917"]},"physDesc":[{"extent":"9 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"2016","dateIssuedKey":"2016"}],"recId":"1587334917","person":[{"family":"Hofheinz","display":"Hofheinz, Ralf-Dieter","given":"Ralf-Dieter","role":"aut"},{"given":"Ulrich","role":"aut","display":"Ronellenfitsch, Ulrich","family":"Ronellenfitsch"}],"name":{"displayForm":["R.-D. Hofheinz, U. Ronellenfitsch, S. Kubicka, A. Falcone, I. Burkholder, and U.T. Hacker"]},"language":["eng"],"title":[{"title_sort":"Treatment with antiangiogenic drugs in multiple lines in patients with metastatic colorectal cancer","title":"Treatment with antiangiogenic drugs in multiple lines in patients with metastatic colorectal cancer","subtitle":"meta-analysis of randomized trials"}]} 
SRT |a HOFHEINZRATREATMENTW2016